Design Therapeutics is a pre-revenue biotech focused on Friedreich's ataxia, with its lead candidate DT-216 undergoing a pivotal Phase 1 trial. The company's fundamental outlook hinges on successful clinical execution, but its financial position is precarious:...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.32+7.1% vs -$0.34 | — vs — |
Q2 2026 Apr 28, 2026 | -$0.29+19.4% vs -$0.36 | — vs — |
Q2 2026 Mar 9, 2026 | -$0.27+28.9% vs -$0.38 | — vs — |
Q4 2025 Nov 5, 2025 | -$0.30+11.8% vs -$0.34 | — vs — |
Bank of New York Mellon Corp acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ: DSGN) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 92,069 shares of the company's stock, valued at approximately $1,332,000. Bank of New York
CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m.
BlackRock Inc. acquired a new position in Design Therapeutics, Inc. (NASDAQ: DSGN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,660,024 shares of the company's stock, valued at approximately $38,491,000. BlackRock Inc. owned about 4.25% of Design
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.
Benchmark DSGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Design Therapeutics, Inc. (DSGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.36 | $771.97M | -10.13 | — | — | -30.7% | — | |
| $3.81 | $206.16M | -3.23 | -100% | — | -28.54% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $26.38 | $3.3B | -202.92 | 91.34% | 6.15% | 15.05% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — |
Design Therapeutics, Inc. (DSGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Design Therapeutics, Inc. (DSGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 11, 2026·SEC
May 18, 2026·SEC
Get notified when DSGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Design Therapeutics, Inc. (DSGN) stock FAQ — growth, dividends, profitability & financials explained
Design Therapeutics, Inc. (DSGN) reported a net loss of $70.8M for fiscal year 2025.
Design Therapeutics, Inc. (DSGN) has a return on equity (ROE) of -30.7%. Negative ROE indicates the company is unprofitable.
Design Therapeutics, Inc. (DSGN) had negative free cash flow of $55.1M in fiscal year 2025, likely due to heavy capital investments.
